This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

49/100

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Caregiving

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

The sirtuin pathway, which is most notable for its association with the anti-ageing effects of calorie restriction, has received particular attention, and pharmacological or transgenic upregulation of the sirtuin pathway has shown promising results in laboratory models of ageing. Because α-secretase is the enzyme responsible for the non-amyloidogenic cleavage of APP, upregulation of α-secretase shifts APP processing to reduce the pathological accumulation of the presumptive toxic Aβ species that results from β-secretase and γ-secretase activity.

What this study adds

Evidence grade: Low

This is a narrative review. This 2011 review looks at the sirtuin pathway, which is best known for its link to the anti-ageing effects of calorie restriction. It reports that boosting the pathway with drugs or genetic changes "has shown promising results in laboratory models of ageing".

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Bonda, D. J., Lee, H. G., Camins, A., Pallàs, M., Casadesus, G., Smith, M. A., et al. (2011). The sirtuin pathway in ageing and Alzheimer disease: mechanistic and therapeutic considerations. The Lancet. Neurology. https://doi.org/10.1016/s1474-4422(11)70013-8

Vancouver

Bonda DJ, Lee HG, Camins A, Pallàs M, Casadesus G, Smith MA, et al. The sirtuin pathway in ageing and Alzheimer disease: mechanistic and therapeutic considerations. The Lancet. Neurology. 2011. doi:10.1016/s1474-4422(11)70013-8. PMID: 21349442.

BibTeX

@article{bonda2011-21349442,
  author  = {Bonda, D. J. and Lee, H. G. and Camins, A. and Pallàs, M. and Casadesus, G. and Smith, M. A. and Zhu, X.},
  title   = {{The sirtuin pathway in ageing and Alzheimer disease: mechanistic and therapeutic considerations}},
  journal = {The Lancet. Neurology},
  year    = {2011},
  doi     = {10.1016/s1474-4422(11)70013-8},
  pmid    = {21349442},
  url     = {https://doi.org/10.1016/s1474-4422(11)70013-8}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

How to read this study

Design: this is a narrative review. It summarises a field without a fixed search method, so it shows how authors read the evidence rather than measuring it. Use it to find the primary studies, not as a result in itself.
Size: the record gives no participant count. Look for one in the original before trusting a pattern.
Effect: the record gives no effect size, so the summary above cannot say how large any difference was.

What the evidence grade means here

This page is graded low. alzhub.org assigns the grade automatically from keywords in the abstract, not from reading the paper. Low means the abstract matched neither pattern. It is the default label, and it does not mean the work is poor; many sound lab and imaging papers land here. It can add at most 5 of the 100 points in the study score, and it is a label about design, not a verdict on whether the findings are true.

New to reading papers? Six questions to ask of any Alzheimer’s study · how we score.

Key findings

The sirtuin pathway, which is most notable for its association with the anti-ageing effects of calorie restriction, has received particular attention, and pharmacological or transgenic upregulation of the sirtuin pathway has shown promising results in laboratory models of ageing.
Because α-secretase is the enzyme responsible for the non-amyloidogenic cleavage of APP, upregulation of α-secretase shifts APP processing to reduce the pathological accumulation of the presumptive toxic Aβ species that results from β-secretase and γ-secretase activity.

Why it matters

This 2011 review looks at the sirtuin pathway, which is best known for its link to the anti-ageing effects of calorie restriction. It reports that boosting the pathway with drugs or genetic changes "has shown promising results in laboratory models of ageing". It also explains that increasing α-secretase moves APP processing away from the route that makes the "presumptive toxic" amyloid-beta. These are lab findings and background biology, not evidence that any diet, supplement or drug helps people with Alzheimer's.

New to this subject? Start with our plain-English guide: Caregiving →

Study details

Evidence strengthLow

How this study scored 49/100

Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

Component	Points	Why
Journal tier	9 / 10	Tier 2 — leading specialty journal (The Lancet. Neurology)
Journal's citation record	3 / 4	The Lancet Neurology: journal h-index 457 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	1 / 5	2011 — within 20 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded	0 / 2	No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	5 / 7	Cited 221 times (OpenAlex, 2026-10-10)
Citations per year	3 / 5	13.0 citations a year over 17 year(s) since 2011
Impact for its field and year	4 / 6	Cited 10.8× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	2 / 6	Cited by 7 other studies in this library
Still being cited	2 / 4	Cited 31 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	4 / 4	Last-listed author Xiongwei Zhu: h-index 105 (OpenAlex, whole career)
Institution's track record	1 / 3	Case Western Reserve University: institution h-index 1,159 (OpenAlex)
Multicenter collaboration	2 / 3	OpenAlex lists 4 institution(s) in 2 countries
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 21349442)
Free to read	0 / 2	Behind a paywall — scores zero
Total	49 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

7 studies in the alzhub library list this one in their references.

Related studies in Caregiving from nearby years

Also tagged “precursor”

1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Caregiving

See all studies in Caregiving →